Kolesar JM - Search Results

1

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance.

Gorski JW, Zhang Z, McCorkle JR, DeJohn JM, Wang C, Miller RW, Gallion HH, Dietrich CS, Ueland FR, Kolesar JM. Gorski JW, et al. Among authors: kolesar jm. Biomedicines. 2021 Aug 16;9(8):1021. doi: 10.3390/biomedicines9081021. Biomedicines. 2021. PMID: 34440225 Free PMC article.

2

Pharmacogenomic potential in advanced cancer patients.

Nichols D, Arnold S, Weiss HL, Wu J, Durbin EB, Miller R, Kolesar J. Nichols D, et al. Am J Health Syst Pharm. 2019 Mar 19;76(7):415-423. doi: 10.1093/ajhp/zxy079. Am J Health Syst Pharm. 2019. PMID: 31361818 Free PMC article.

3

Cell-Derived Vesicles for in Vitro and in Vivo Targeted Therapeutic Delivery.

Snell AA, Neupane KR, McCorkle JR, Fu X, Moonschi FH, Caudill EB, Kolesar J, Richards CI. Snell AA, et al. ACS Omega. 2019 Jul 24;4(7):12657-12664. doi: 10.1021/acsomega.9b01353. eCollection 2019 Jul 31. ACS Omega. 2019. PMID: 31460386 Free PMC article.

4

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.

Burgess BT, Anderson AM, McCorkle JR, Wu J, Ueland FR, Kolesar JM. Burgess BT, et al. Among authors: kolesar jm. Diagnostics (Basel). 2020 Feb 22;10(2):121. doi: 10.3390/diagnostics10020121. Diagnostics (Basel). 2020. PMID: 32098452 Free PMC article.

5

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer.

Gorski JW, Ueland FR, Kolesar JM. Gorski JW, et al. Among authors: kolesar jm. Diagnostics (Basel). 2020 May 5;10(5):279. doi: 10.3390/diagnostics10050279. Diagnostics (Basel). 2020. PMID: 32380689 Free PMC article. Review.

6

Factors Predicting Participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky.

Riggs MJ, Huang B, Chen Q, Bocklage T, Schuh MR, Poi M, Villano JL, Cavnar MJ, Arnold SM, Miller RW, Ueland FR, Kolesar JM. Riggs MJ, et al. Among authors: kolesar jm. J Rural Health. 2022 Jan;38(1):5-13. doi: 10.1111/jrh.12492. Epub 2020 Jul 6. J Rural Health. 2022. PMID: 32633045 Free PMC article.

7

MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations.

Liu S, Liu J, Xie Y, Zhai T, Hinderer EW, Stromberg AJ, Vanderford NL, Kolesar JM, Moseley HNB, Chen L, Liu C, Wang C. Liu S, et al. Among authors: kolesar jm. Bioinformatics. 2021 Jun 9;37(9):1189-1197. doi: 10.1093/bioinformatics/btaa957. Bioinformatics. 2021. PMID: 33165532 Free PMC article.

8

DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden.

Riggs MJ, Lin N, Wang C, Piecoro DW, Miller RW, Hampton OA, Rao M, Ueland FR, Kolesar JM. Riggs MJ, et al. Among authors: kolesar jm. PLoS One. 2020 Dec 30;15(12):e0244558. doi: 10.1371/journal.pone.0244558. eCollection 2020. PLoS One. 2020. PMID: 33378353 Free PMC article.

9

MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer.

Hutchcraft ML, Gallion HH, Kolesar JM. Hutchcraft ML, et al. Among authors: kolesar jm. Diagnostics (Basel). 2021 Jan 6;11(1):84. doi: 10.3390/diagnostics11010084. Diagnostics (Basel). 2021. PMID: 33419231 Free PMC article. Review.

10

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer.

Schweer D, McCorkle JR, Rohr J, Tsodikov OV, Ueland F, Kolesar J. Schweer D, et al. Biomedicines. 2021 Jan 12;9(1):70. doi: 10.3390/biomedicines9010070. Biomedicines. 2021. PMID: 33445667 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page